Atrys Health Overview
- Founded
-
2007
- Status
-
Public
- Employees
-
2,397
- Stock Symbol
-
ATRY
- Investments
-
19
- Share Price
-
$5.96
- (As of Thursday Closing)
Atrys Health General Information
Description
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
Contact Information
Website
www.atryshealth.com
Formerly Known As
Althia, eDiagnostic
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Services
Stock Exchange
MAD
Primary Office
- C Príncipe de Vergara 132
- 1 Piso
- 28002 Madrid
- Spain
+34 917 00 00 00
Atrys Health Timeline
Atrys Health Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.96 | $6.03 | $5.06 - $9.79 | $452M | 75.9M | 18.1K | -$0.50 |
Atrys Health Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 689,825 | 901,849 | 314,407 | 142,206 |
| Revenue | 191,574 | 143,075 | 35,789 | 16,609 |
| EBITDA | 14,666 | 6,020 | 3,110 | 3,550 |
| Net Income | (25,715) | (27,494) | (6,324) | (117) |
| Total Assets | 728,188 | 640,420 | 222,588 | 98,623 |
| Total Debt | 252,474 | 231,555 | 89,144 | 40,067 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Atrys Health Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Atrys Health Patents
Atrys Health Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2848365-A1 | Methods for prognosis of diffuse large b-cell lymphoma | Inactive | 12-Sep-2011 | 000000000000 | |
| EP-2568290-A1 | Methods for prognosis of diffuse large b-cell lymphoma | Active | 12-Sep-2011 | 000000000000 | 0 |
| EP-2568290-B1 | Methods for prognosis of diffuse large b-cell lymphoma | Active | 12-Sep-2011 | 000000000000 | |
| ES-2634254-T3 | Methods for prognosis of diffuse large b lymphocyte lymphoma | Active | 12-Sep-2011 | G01N33/57407 |
Atrys Health Executive Team (11)
Atrys Health Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Isabel Lozano | Atrys Health | Chief Executive Officer & Board Member | 000 0000 |
Atrys Health Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Atrys Health Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Atrys Health Investments & Acquisitions (19)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 00000(0 | 09-Jan-2023 | 000000000 | Buildings and Property | ||
| 00000000 | 27-Dec-2022 | 0000000000 | 00.00 | Diagnostic Equipment | 00 000000 |
| 000000 000000 | 27-Dec-2022 | 0000000000 | Clinics/Outpatient Services | ||
| 00000 0000000 | 23-Jun-2022 | 0000000000 | 00000 | Clinics/Outpatient Services | 00 000000 |
| SIMM Molecular | 04-Jan-2022 | Merger/Acquisition | 00.000 | Hospitals/Inpatient Services | 00 000000 |
Atrys Health Subsidiaries (7)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Genetyca-ICM | Laboratory Services (Healthcare) | Porto, Portugal | 2018 |
| 0000 000000000 | Hospitals/Inpatient Services | Barcelona, Spain | 0000 |
| 00000000 | Diagnostic Equipment | Las condes, Chile | 0000 |
| 0000000 | Clinics/Outpatient Services | Sao Paulo, Brazil | 0000 |
| 00000 000000000 | Clinics/Outpatient Services | Almeria, Spain | 0000 |
Atrys Health ESG
Risk Overview
Risk Rating
Updated December, 10, 2022
21.96 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
00.00
Percentile
Healthcare
Industry
00 of 601
Rank
00.00
Percentile
Medical Services
Subindustry
00 of 108
Rank
00.00
Percentile
